$TRANSCENTA-B (06628.HK)$
bottom

$TRANSCENTA-B (06628.HK)$ backed by Lilly and Temasek, high success rate for Claudin 18.3

$TRANSCENTA-B (06628.HK)$ On October 9, the CDE website showed that The application for clinical trial of MBOS TST005 injection was accepted by the Food and Drug Administration, and the indication is solid tumor. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein to initiate a global clinical study.